Impact of Care Coordination on 30-Day Readmission, Mortality, and Costs for Heart Failure
AJMC,
Enhancing coordination of care has the potential to increase the value of heart failure care.
Enhancing coordination of care has the potential to increase the value of heart failure care.
Byline: Xiaodong Li, Xinyue Li, Baoxin Li and Xiangdong Wang Keywords: Diabetic Nephropathy, Chronic kidney disease, Risk…
ABSTRACT Objective: To evaluate the cost-benefit of sacubitril/valsartan in adults with heart failure (HF) enrolled in a state…
Sodium restriction has long been the cornerstone of self-care for patients with heart failure (HF), given the relevance of…
Sodium restriction has long been the cornerstone of self-care for patients with heart failure (HF), given the relevance of…
SNOWMASS, COLO. – If ever there was a major chronic disease that’s teed up and ready to be stamped into submission through…
One might expect general agreement between what physician authors and companies publicly declare about payments and other…
One might expect general agreement between what physician authors and companies publicly declare about payments and other…
Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF…
Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF…
"Understanding the correlation between time since hospitalization and treatment benefit may help inform optimization of care…
EAST HANOVER, N.J., Nov. 17, 2019 /PRNewswire/ -- Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF…
Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF…
Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF…
SOURCE Novartis Pharmaceuticals Corporation EAST HANOVER, N.J., Nov. 17, 2019 /PRNewswire/ -- Entresto (sacubitril/valsartan…
SOURCE Novartis Pharmaceuticals Corporation EAST HANOVER, N.J., Nov. 17, 2019 /PRNewswire/ -- Entresto (sacubitril/valsartan…
Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF…
EAST HANOVER, N.J., Nov. 17, 2019 /PRNewswire/ -- Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF…
PR Newswire EAST HANOVER, N.J., Nov. 17, 2019 EAST HANOVER, N.J., Nov. 17, 2019 /PRNewswire/ -- Entresto (sacubitril/valsartan…
Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF…
Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF…
Entresto (sacubitril/valsartan) reduced the composite of total (first and recurrent) heart failure hospitalizations and…
Entresto (sacubitril/valsartan) reduced the composite of total (first and recurrent) heart failure hospitalizations and…
Entresto (sacubitril/valsartan) reduced the composite of total (first and recurrent) heart failure hospitalizations and…
Entresto (sacubitril/valsartan) reduced the composite of complete (first and recurrent) middle failure hospitalizations and…
Entresto (sacubitril/valsartan) reduced the composite of total (first and recurrent) heart failure hospitalizations and…
Novartis plans to engage in conversations with clinical experts and regulators on next steps Basel, July 29, 2019 - Novartis…
Novartis plans to engage in conversations with clinical experts and regulators on next steps Basel, July 29, 2019 - Novartis…
Novartis International AG / Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved…
Novartis plans to engage in conversations with clinical experts and regulators on next steps Basel, July 29, 2019 - Novartis…
PARAGON study narrowly misses statistical significance on the primary endpoint; overall safety profile confirmed Totality of…
Jones, Sarah L., et al. " Critical Care and Resuscitation 17.3 (2015): 223. Joannidis, Michael, Sebastian J.
—New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsartan (Entresto) continued…
March 27, 2019 —New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsartan (Entres…
Outcomes from PIONEER-HF 4-week open-label extension reinforce initial 8-week findings, showing Entresto® (sacubitril/valsartan…
/PRNewswire/ -- Novartis announced today new results from a 4-week extension of the landmark PIONEER-HF trial, presented as a…
SOURCE Novartis Pharmaceuticals Corporation - Outcomes from PIONEER-HF 4-week open-label extension reinforce initial 8-week…
SOURCE Novartis Pharmaceuticals Corporation - Outcomes from PIONEER-HF 4-week open-label extension reinforce initial 8-week…
SOURCE Novartis Pharmaceuticals Corporation - Outcomes from PIONEER-HF 4-week open-label extension reinforce initial 8-week…
SOURCE Novartis Pharmaceuticals Corporation - Outcomes from PIONEER-HF 4-week open-label extension reinforce initial 8-week…
/PRNewswire/ -- Novartis announced today new results from a 4-week extension of the landmark PIONEER-HF trial, presented as a…
- Outcomes from PIONEER-HF 4-week open-label extension reinforce initial 8-week findings, showing Entresto® (sacubitril/valsartan…
- Outcomes from PIONEER-HF 4-week open-label extension reinforce initial 8-week findings, showing Entresto® (sacubitril/valsartan…
- Outcomes from PIONEER-HF 4-week open-label extension reinforce initial 8-week findings, showing Entresto® (sacubitril/valsartan…
EXPERT ANALYSIS FROM THE ANNUAL CARDIOVASCULAR CONFERENCE AT SNOWMASS SNOWMASS, COLO.
HF remains a complex clinical syndrome. It is estimated that nearly 6 million Americans have HF and more than 800,000 new cases…
This article was sponsored by Novartis Pharmaceuticals Corporation. Full Prescribing Information INCLUDING Boxed WARNING Please…
(MedPage Today) -- Hospitalized patients with a secondary diagnosis of heart failure received fewer lifesaving assessments and…